Integer (ITGR) is facing macroeconomic uncertainty related to tariffs, Oppenheimer said in a note Friday as it lowered its rating on the stock.

"We are adopting a wait and see stance," Oppenheimer said.

The firm said it is "fundamentally constructive" on Integer because of the company's exposure to high-growth MedTech segments.

"Our downgrade is a reflection of the stock being at our price target, and the uncertainty around possible tariff-induced structural dislocations," Oppenheimer said.

Oppenheimer downgraded its rating on Integer stock to perform from outperform, and removed its $138 price target.